Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2005
10/20/2005US20050232942 Virulence genes, proteins, and their use
10/20/2005US20050232927 Using notch gene expression as evaluative tool in detecting breast cancer
10/20/2005US20050232925 Protease activity of thrombin inhibits angiogenesis
10/20/2005US20050232923 Methods and compositions for treating MCP-1 related pathologies
10/20/2005US20050232922 Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
10/20/2005US20050232916 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
10/20/2005US20050232914 Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof
10/20/2005US20050232913 Short chain neurotoxin from sea snake-lapemis hardwickii and genes encoding the neurotoxin
10/20/2005US20050232912 Enzyme phosphorylating ser46 of p53
10/20/2005US20050232911 Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
10/20/2005US20050232907 Use of herpes vectors for tumor therapy
10/20/2005US20050232906 Adjuvant preparation for the induction of specific immunity
10/20/2005US20050232903 Mincing tissue, culturing with growth factors, bone morphogenetic protein or vitamin D; propagating in alginate, agarose and collagen to form 3-dimensional structure
10/20/2005US20050232902 Injectable bioartificial tissue matrix
10/20/2005US20050232901 Materials and methods for treating or preventing oxalate-related disease
10/20/2005US20050232899 Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
10/20/2005US20050232898 Stabilized protein compositions
10/20/2005US20050232896 Cd137 as a proliferation factor for hematopoietic stem cells
10/20/2005US20050232874 Compound and method of treatment for fungal pathologies of the oral cavity
10/20/2005US20050232872 Compositions and methods for enhancing receptor-mediated cellular internalization
10/20/2005US20050231682 Composition for stabilizing corneal tissue during or after orthokeratology lens wear
10/20/2005US20050230303 Device for concentrating and stabilizing conjugated estrogens from mare urine
10/20/2005CA2853272A1 Synthesis of boronic ester and acid compounds
10/20/2005CA2565324A1 Method of reducing c-reactive protein using growth hormone secretagogues
10/20/2005CA2563513A1 Remedy for neurodegenerative diseases
10/20/2005CA2563379A1 Human glp-1 mimetibodies, compositions, methods and uses
10/20/2005CA2563313A1 Modulation of nkg2d
10/20/2005CA2563276A1 Composition comprising colony stimulating factor for treatment of a localised bacterial infection and bacterial related disease
10/20/2005CA2562957A1 Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
10/20/2005CA2562385A1 Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
10/20/2005CA2561958A1 Composition and method for inhibiting platelet aggregation
10/20/2005CA2561954A1 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
10/20/2005CA2561947A1 Preventives/remedies for cancer
10/20/2005CA2561912A1 Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury
10/20/2005CA2561907A1 Composition comprising a jnk inhibitor and cyclosporin
10/20/2005CA2561833A1 Oligopeptides for reducing elevated blood urea concentration
10/20/2005CA2561809A1 Bmp-7 variants with improved properties
10/20/2005CA2561645A1 A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern
10/20/2005CA2561593A1 Antiobesity drug
10/20/2005CA2561222A1 Combination dosing regimen for erythropoietin
10/20/2005CA2561171A1 Synthetic chemokines, methods of manufacture, and uses
10/20/2005CA2561164A1 Steroid sparing agents and their use
10/20/2005CA2561163A1 Stabilised tat antigen and the use thereof for anti-hiv vaccination
10/20/2005CA2560956A1 Amphipathic glycopeptides
10/20/2005CA2560726A1 Peptides and peptidomimetics binding to cd23
10/20/2005CA2558829A1 Methods for treating viral infection using il-28 and il-29 cysteine mutants
10/19/2005EP1586649A2 Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
10/19/2005EP1586646A2 Lawsonia intracellularis vaccine
10/19/2005EP1586644A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour development and for wound healing
10/19/2005EP1586643A2 Polypeptides and nucleic acids encoding same
10/19/2005EP1586642A2 Tumor supressor genes, proteins encoded thereby and use of said genes and proteins
10/19/2005EP1586641A2 Compounds for the treatment of hypercalcemia and hypocalcemia
10/19/2005EP1586635A1 Fusion proteins with parts of immunoglobulins, their production and use
10/19/2005EP1586586A2 Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament
10/19/2005EP1586584A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids
10/19/2005EP1586583A2 Compounds that block C5a complement receptor and their use in therapy
10/19/2005EP1586582A1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
10/19/2005EP1586581A2 Non-Mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
10/19/2005EP1586580A2 Process for the purification of daptomycin
10/19/2005EP1586334A1 G-CSF conjugates with peg
10/19/2005EP1586332A1 Combined use of carnosinase inhibitor with l-carnosines and composition
10/19/2005EP1586329A1 Botulinum toxin pharmaceutical compositions
10/19/2005EP1586328A1 Agent for improving life expectancy in therapy of malignant tumor
10/19/2005EP1586327A1 Bone replacement material comprising factor XIII
10/19/2005EP1586326A1 Pharmaceutical compositions for treating neuronal damage and neurodegenerative diseases
10/19/2005EP1586325A1 Drugs containing galectin 9
10/19/2005EP1586324A1 Ophthalmic therapeutic composition
10/19/2005EP1586312A1 Agent for dissolving dental calculi and dental caries
10/19/2005EP1586309A1 Polymeric delivery formulations of leuprolide with improved efficacy
10/19/2005EP1585959A2 Extended glucagon-like peptide-1 analogs
10/19/2005EP1585956A2 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
10/19/2005EP1585817A2 Conjugates comprising a biodegradable polymer and uses therefor
10/19/2005EP1585816A2 Crystal structure of the set 7/9 histone methyl transferase active catalytic domain and uses thereof
10/19/2005EP1585814A1 Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
10/19/2005EP1585805A2 Phenylalanine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
10/19/2005EP1585764A2 Rantes-derived peptides with anti-hiv activity
10/19/2005EP1585763A2 Protein domain related to deafness, osteoarthritis and abnormal cell proliferation
10/19/2005EP1585762A1 Means for regulating the expression of human isoforms of ant
10/19/2005EP1585757A2 Peptide deformylase inhibitors
10/19/2005EP1585560A2 Delivery of molecules and complexes to mammalian cells in vivo
10/19/2005EP1585556A1 Compositions comprising bone marrow cells, demineralized bone matrix and various site-reactive polymers for use in the induction of bone and cartilage formation
10/19/2005EP1585555A2 Compositions and methods of using collagen and mmpi
10/19/2005EP1585546A2 Kim-1 antagonists and use to modulate immune system
10/19/2005EP1585545A2 Methods of inducing and maintaining immune tolerance
10/19/2005EP1585541A2 Pharmaceutical compositions comprising insulin and legends of insulin hexamer
10/19/2005EP1585540A1 Medicament and use thereof for tumor therapy
10/19/2005EP1585539A2 Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof
10/19/2005EP1585538A1 Modified hemoglobin and methods of making same
10/19/2005EP1585537A1 1-desamino-8-d-arginyl vasopressin analogs
10/19/2005EP1585536A2 Method of treatment of conditions by administration of streptolysin o
10/19/2005EP1585535A2 Pthrp-derived modulators of smooth muscle proliferation
10/19/2005EP1585532A2 Topical anti-infective formulations
10/19/2005EP1585524A2 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus
10/19/2005EP1585520A1 Therapeutic formulations for the treatment of beta-amyloid related diseases
10/19/2005EP1585503A2 Improved oral delivery of peptides
10/19/2005EP1585499A2 Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x
10/19/2005EP1585484A2 Hepatocyte growth factor variants
10/19/2005EP1585478A2 Use of synergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections
10/19/2005EP1570055A4 23565, a novel human zinc carboxypeptidase family member and uses thereof
10/19/2005EP1492879A4 Chimeric cannulae proteins, nucleic acids encoding them and methods for making and using them
1 ... 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 ... 3163